Similarly, post-hoc analyses of two large-scale trials (FINGER and MAPT) have shown that individuals at increased risk of future cognitive decline—such as APOE-ε4 carriers or those with positive amyloid PET scans—tend to derive greater cognitive benefits from MLI compared to non-carriers. Here, APOE is linked to Mental deterioration.